The Significance of Serum Tumor Markers CEA, Ca 19-9, Ca 125, Ca 15-3, and AFP in Patients Scheduled for Orthotopic Liver Transplantation: Do Elevated Levels Really Mean Malignancy?

被引:1
作者
Baskiran, Deniz Yavuz [1 ]
Sarigoz, Talha [2 ]
Baskiran, Adil [3 ]
Yilmaz, Sezai [3 ]
机构
[1] Inonu Univ, Turgut Ozal Med Ctr, Dept Publ Hlth, Malatya, Turkey
[2] Kayseri City Hosp, Dept Gen Surg, Kayseri, Turkey
[3] Inonu Univ, Turgut Ozal Med Ctr, Inst Liver Transplantat, Malatya, Turkey
关键词
Chronic liver disease; Liver transplantation; Hepacivirus; Hepatitis B virus; Biomarkers; HEPATITIS-B; CA19-9; PROGNOSIS; FAILURE; DISEASE; VIRUS;
D O I
10.1007/s12029-021-00798-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim and Background Preparation of the patients for liver transplantation is a meticulous process and includes evaluation of tumor markers to rule out occult malignancy. The present study evaluated the significance of serum tumor markers in patients bound for liver transplantation due to viral and other etiologies of liver failure. Patients and Methods Three hundred eighty-one patients who underwent liver transplantation were included in the study. Demographic data, model for end stage liver disease (MELD) scores, and serum tumor marker levels were prospectively collected. Results AFP levels were significantly higher in viral etiologies when compared to other etiologies (p < 0.05). Ca 19-9 was significantly higher in viral etiologies (p < 0.05). Among the viral etiologies, HCV-related liver failure had higher carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (Ca 19-9) levels (p < 0.05). A correlation was found between increasing MELD scores and serum levels of tumor markers (p < 0.05). Conclusions Tumor markers such as AFP, CEA, Ca 125, and Ca 19-9 can be elevated in end stage liver disease. Their levels vary according to etiology and severity of disease. The diagnostic capabilities of these markers are reduced in end stage liver disease setting but they contribute to the evaluation of the pathophysiology of chronic liver disease. Transplantation can be performed safely in cases with high tumor marker levels provided that any occult malignancy is ruled out by means of imaging and endoscopic techniques. Tumor markers can guide the physician in determining the severity of liver cirrhosis, and further studies are needed to validate such a relationship.
引用
收藏
页码:442 / 446
页数:5
相关论文
共 38 条
  • [31] Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET/CT
    Arslan, Esra
    Aral, Hale
    Aksoy, Tamer
    Afsar, Cigdem Usul
    Karabulut, Senem
    Trabulus, Fadime Didem Can
    Gursu, Riza Umar
    Cermik, Tevfik Fikret
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (05): : 673 - 679
  • [32] The utility and prognostic value of CA 19-9 and CEA serum markers in the long-term follow up of patients with colorectal cancer. A single-center experience over 13 years
    Tumay, Volkan
    Guner, Osman Serhat
    [J]. ANNALI ITALIANI DI CHIRURGIA, 2020, 91 (05) : 494 - 503
  • [33] Diagnostic values of serum tumor markers Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinoma
    Yuan, Chuanshu
    Yang, Kai
    Tang, Hong
    Chen, Dan
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3381 - 3386
  • [34] Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment
    Kosuke Kobayashi
    Yoshihiro Ono
    Yuki Kitano
    Atsushi Oba
    Takafumi Sato
    Hiromichi Ito
    Yoshihiro Mise
    Eiji Shinozaki
    Yosuke Inoue
    Kensei Yamaguchi
    Akio Saiura
    Yu Takahashi
    [J]. Annals of Surgical Oncology, 2023, 30 : 7338 - 7347
  • [35] Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment
    Kobayashi, Kosuke
    Ono, Yoshihiro
    Kitano, Yuki
    Oba, Atsushi
    Sato, Takafumi
    Ito, Hiromichi
    Mise, Yoshihiro
    Shinozaki, Eiji
    Inoue, Yosuke
    Yamaguchi, Kensei
    Saiura, Akio
    Takahashi, Yu
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7338 - 7347
  • [36] Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA
    Mitsunori Ushigome
    Hideaki Shimada
    Yasuyuki Miura
    Kimihiko Yoshida
    Tomonori Kaneko
    Takamaru Koda
    Yasuo Nagashima
    Takayuki Suzuki
    Satoru Kagami
    Kimihiko Funahashi
    [J]. International Journal of Clinical Oncology, 2020, 25 : 622 - 632
  • [37] Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA
    Ushigome, Mitsunori
    Shimada, Hideaki
    Miura, Yasuyuki
    Yoshida, Kimihiko
    Kaneko, Tomonori
    Koda, Takamaru
    Nagashima, Yasuo
    Suzuki, Takayuki
    Kagami, Satoru
    Funahashi, Kimihiko
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 622 - 632
  • [38] Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study
    Doppenberg, Deesje
    Stoop, Thomas F.
    van Dieren, Susan
    Katz, Matthew H. G.
    Janssen, Quisette P.
    Nasar, Naaz
    Prakash, Laura R.
    Theijse, Rutger T.
    Tzeng, Ching-Wei D.
    Wei, Alice C.
    Zureikat, Amer H.
    Groot Koerkamp, Bas
    Besselink, Marc G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1919 - 1932